
<meta data-rh="true" name="docsearch:language" content="en">
<meta data-rh="true" name="docsearch:version" content="current">
<meta data-rh="true" name="docsearch:docusaurus_tag" content="docs-default-current">
        ---
sidebar_position: 53
---
           <p class="stitle-article-norm">Clinical evaluation consultation procedure for certain class III and class IIb devices</p>
   <p class="norm">1.&nbsp;&nbsp;In addition to the procedures 
applicable pursuant to Article&nbsp;52, a notified body shall also 
follow the procedure regarding clinical evaluation consultation as 
specified in Section&nbsp;5.1 of Annex&nbsp;IX or as referred to in 
Section&nbsp;6 of Annex&nbsp;X, as applicable, when performing a 
conformity assessment of the following devices:</p>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(a)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">class III implantable devices, and</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(b)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">class IIb active devices intended to administer
 and/or remove a medicinal product, as referred to in Section&nbsp;6.4 
of Annex&nbsp;VIII (Rule 12).</p>
      </div>
   </div>
   <p class="norm">2.&nbsp;&nbsp;The procedure referred to in paragraph&nbsp;1 shall not be required for the devices referred to therein:</p>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(a)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">in the case of renewal of a certificate issued under this Regulation;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(b)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">where the device has been designed by modifying
 a device already marketed by the same manufacturer for the same 
intended purpose, provided that the manufacturer has demonstrated to the
 satisfaction of the notified body that the modifications do not 
adversely affect the benefit-risk ratio of the device; or</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(c)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">where the principles of the clinical evaluation
 of the device type or category have been addressed in a CS referred to 
in Article&nbsp;9 and the notified body confirms that the clinical 
evaluation of the manufacturer for this device is in compliance with the
 relevant CS for clinical evaluation of that kind of device.</p>
      </div>
   </div>
   <p class="norm">3.&nbsp;&nbsp;The notified body shall notify the 
competent authorities, the authority responsible for notified bodies and
 the Commission through the electronic system referred to in 
Article&nbsp;57 of whether or not the procedure referred to in 
paragraph&nbsp;1 of this Article&nbsp;is to be applied. That 
notification shall be accompanied by the clinical evaluation assessment 
report.</p>
   <p class="norm">4.&nbsp;&nbsp;The Commission shall draw up an annual 
overview of devices which have been subject to the procedure specified 
in Section&nbsp;5.1 of Annex&nbsp;IX and referred to in Section&nbsp;6 
of Annex&nbsp;X. The annual overview shall include the notifications in 
accordance with paragraph&nbsp;3 of this Article&nbsp;and point&nbsp;(e)
 of Section&nbsp;5.1 of Annex&nbsp;IX and a listing of the cases where 
the notified body did not follow the advice from the expert panel. The 
Commission shall submit this overview to the European Parliament, to the
 Council and to the MDCG.</p>
   <p class="norm">5.&nbsp;&nbsp;The Commission shall by 27 May 2025 
draw up a report on the operation of this Article&nbsp;and submit it to 
the European Parliament and to the Council. The report shall take into 
account the annual overviews and any available relevant recommendations 
from the MDCG. On the basis of that report the Commission shall, if 
appropriate, make proposals for amendments to this Regulation.</p>